Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain

Executive Summary

Botox was a game-changer, which means challengers to Allergan's blockbuster are on the way. Dermal fillers and devices also have an important role, but dermatologists say innovation is needed to fill treatment gaps. Business development is ongoing to expand companies' product portfolios.

Advertisement

Related Content

Keeping Track: Shionogi, Fresenius Kabi Join July Approval Parade; Busy August Expected
Keeping Track: A Diverse Array Of Approvals, A CRL For Evolus' Botox Competitor, And Coherus Refiles Neulasta Biosimilar
Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It
Mylan Set To Develop Biosimilar Botox In Deal With Revance
Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow
Revance's Long-Acting RT002 Will Have Slow-Moving Impact On Allergan
Allergan Bolsters Blockbuster Botox With Topical Toxin Buy
Allergan buys chin fat firm Kythera for $2.1bn

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel